Trevi Therapeutics, Inc. Earnings Per Share (Diluted)
Trevi Therapeutics, Inc. (TRVI) reported Earnings Per Share (Diluted) of -$0.11 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- Trevi Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.11.
- Trevi Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.09.
- Trevi Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.06.
- Trevi Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.08.
- Trevi Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$0.32.
- Trevi Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$0.47.
- Trevi Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was -$0.29.
- Trevi Therapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$0.45.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.11 10-Q · filed 2026-08-06 | -$0.21 10-Q · filed 2026-08-06 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.09 10-Q · filed 2026-05-05 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.14 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.32 10-K · filed 2026-03-17 |
| 2025-09-30 | -$0.08 10-Q · filed 2025-11-13 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.26 10-Q · filed 2025-11-13 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.09 10-Q · filed 2026-08-06 | -$0.18 10-Q · filed 2026-08-06 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.09 10-Q · filed 2026-05-05 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-05-05 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-05-05 |
| 2024-12-31 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.47 10-K · filed 2026-03-17 |
| 2024-09-30 | -$0.13 10-Q · filed 2025-11-13 | -$0.25 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.36 10-Q · filed 2025-11-13 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-06-30 | -$0.12 10-Q · filed 2025-08-07 | -$0.23 10-Q · filed 2025-08-07 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.39 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2024-03-31 | -$0.11 10-Q · filed 2025-05-08 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-04-21 |
| 2023-12-31 | -$0.08 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.29 10-K · filed 2025-03-18 |
| 2023-09-30 | -$0.08 10-Q · filed 2024-11-06 | -$0.15 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.21 10-Q · filed 2024-11-06 | -$0.27 derived: net income ÷ weighted average shares · filed 2024-11-06 |
| 2023-06-30 | -$0.07 10-Q · filed 2024-08-08 | -$0.14 10-Q · filed 2024-08-08 | -$0.19 derived: net income ÷ weighted average shares · filed 2024-08-08 | -$0.30 derived: net income ÷ weighted average shares · filed 2024-08-08 |
| 2023-03-31 | -$0.06 10-Q · filed 2024-05-07 | -$0.12 derived: net income ÷ weighted average shares · filed 2024-05-07 | -$0.23 derived: net income ÷ weighted average shares · filed 2024-05-07 | -$0.35 derived: net income ÷ weighted average shares · filed 2024-05-07 |
| 2022-12-31 | -$0.06 derived: net income ÷ weighted average shares · filed 2024-03-20 | -$0.16 derived: net income ÷ weighted average shares · filed 2024-03-20 | -$0.29 derived: net income ÷ weighted average shares · filed 2024-03-20 | -$0.45 10-K · filed 2024-03-20 |
| 2022-09-30 | -$0.12 10-Q · filed 2023-11-09 | -$0.25 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.44 10-Q · filed 2023-11-09 | -$0.68 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$0.14 10-Q · filed 2023-08-10 | -$0.34 10-Q · filed 2023-08-10 | -$0.59 derived: net income ÷ weighted average shares · filed 2023-08-10 | -$0.88 derived: net income ÷ weighted average shares · filed 2023-08-10 |
| 2022-03-31 | -$0.24 10-Q · filed 2023-05-11 | -$0.52 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$0.84 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$1.28 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$0.61 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$1.07 derived: net income ÷ weighted average shares · filed 2023-03-16 | -$1.49 10-K · filed 2023-03-16 |
| 2021-09-30 | -$0.34 10-Q · filed 2022-11-10 | -$0.82 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.25 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$0.49 10-Q · filed 2022-08-11 | -$0.92 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |